Friedberg noted that chemotherapy combined with an antibody remains a recommended treatment for patients with advanced-stage ...

Dr. Hope Rugo explains how antibody-drug conjugates like Datroway and Trodelvy are shifting the treatment landscape for ...

Fifteen-year follow-up from the S0016 trial found over one-third of patients with follicular lymphoma treated with chemoimmunotherapy had no progression.

ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...

Incidental detection has increased with ubiquitous CT/MRI, inflating early-stage ‘small renal mass’ diagnoses and complicating interpretation of a ~5% rise in <50-year incidence. Obesity, hypertension ...

A personal look at choosing to be a caregiver, the challenges faced, and the lessons learned while supporting a sister through years with cancer. It may simply be because I cannot adequately explain ...

Ipsen withdrew tazemetostat worldwide for follicular lymphoma and epithelioid sarcoma after new trial data suggested a less favorable safety profile than previously characterized. SYMPHONY-1 ...

We are continuing to see an increase in the incidence of kidney cancer in younger patients over time. Maintaining kidney health involves basic lifestyle choices: avoiding obesity, not smoking, and ...

FDA Priority Review was granted for trastuzumab deruxtecan in post-neoadjuvant HER2-positive early breast cancer with residual invasive disease, with a regulatory decision anticipated in Q3 2026.

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

Here are five key takeaways for regarding the use of GLP-1 receptor agonists in patients who are undergoing breast cancer ...

Post-treatment lung health is a longitudinal survivorship issue; nonregenerative parenchymal loss, radiation fibrosis, and ...